1. Home
  2. TNXP vs MDRR Comparison

TNXP vs MDRR Comparison

Compare TNXP & MDRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNXP
  • MDRR
  • Stock Information
  • Founded
  • TNXP 2007
  • MDRR 2015
  • Country
  • TNXP United States
  • MDRR United States
  • Employees
  • TNXP N/A
  • MDRR N/A
  • Industry
  • TNXP Biotechnology: Pharmaceutical Preparations
  • MDRR Real Estate Investment Trusts
  • Sector
  • TNXP Health Care
  • MDRR Real Estate
  • Exchange
  • TNXP Nasdaq
  • MDRR Nasdaq
  • Market Cap
  • TNXP 15.1M
  • MDRR 13.4M
  • IPO Year
  • TNXP N/A
  • MDRR 2018
  • Fundamental
  • Price
  • TNXP $0.13
  • MDRR $12.01
  • Analyst Decision
  • TNXP Strong Buy
  • MDRR
  • Analyst Count
  • TNXP 2
  • MDRR 0
  • Target Price
  • TNXP $53.50
  • MDRR N/A
  • AVG Volume (30 Days)
  • TNXP 35.6M
  • MDRR 5.7K
  • Earning Date
  • TNXP 11-07-2024
  • MDRR 11-11-2024
  • Dividend Yield
  • TNXP N/A
  • MDRR 1.67%
  • EPS Growth
  • TNXP N/A
  • MDRR N/A
  • EPS
  • TNXP N/A
  • MDRR N/A
  • Revenue
  • TNXP $12,458,000.00
  • MDRR $10,168,744.00
  • Revenue This Year
  • TNXP $62.53
  • MDRR N/A
  • Revenue Next Year
  • TNXP $26.17
  • MDRR N/A
  • P/E Ratio
  • TNXP N/A
  • MDRR N/A
  • Revenue Growth
  • TNXP N/A
  • MDRR N/A
  • 52 Week Low
  • TNXP $0.12
  • MDRR $8.24
  • 52 Week High
  • TNXP $22.08
  • MDRR $14.95
  • Technical
  • Relative Strength Index (RSI)
  • TNXP 24.79
  • MDRR 45.78
  • Support Level
  • TNXP $0.14
  • MDRR $11.96
  • Resistance Level
  • TNXP $0.21
  • MDRR $12.30
  • Average True Range (ATR)
  • TNXP 0.01
  • MDRR 0.25
  • MACD
  • TNXP 0.02
  • MDRR -0.06
  • Stochastic Oscillator
  • TNXP 8.70
  • MDRR 6.33

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About MDRR Medalist Diversified REIT Inc.

Medalist Diversified REIT Inc is engaged in the acquisition, reposition, renovation, leasing, and managing of income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its principal objectives include sourcing value-added Investments in markets in which it maintains deep industry relationships and local market knowledge and the creation of value for stockholders by utilizing its relationships and local knowledge of commercial real estate investment, management, and disposition.

Share on Social Networks: